[go: up one dir, main page]

BR9915546A - Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica - Google Patents

Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica

Info

Publication number
BR9915546A
BR9915546A BR9915546-0A BR9915546A BR9915546A BR 9915546 A BR9915546 A BR 9915546A BR 9915546 A BR9915546 A BR 9915546A BR 9915546 A BR9915546 A BR 9915546A
Authority
BR
Brazil
Prior art keywords
infection
rna
ribavirin
combination therapy
chronic hepatitis
Prior art date
Application number
BR9915546-0A
Other languages
English (en)
Inventor
Ashit K Ganguly
Jinping Mccormick
Raymond G Lovey
Frank Bennett
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9915546A publication Critical patent/BR9915546A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"TERAPIA DE COMBINAçãO DE RIBAVIRIN- INTERFERON ALFA PARA A ERRADICAçãO DE HCV-RNA DETECTáVEL EM PACIENTES TENDO INFECçãO POR HEPATITE C CRÈNICA"<D>. Método para o tratamento de um paciente tendo infecção por hepatite C crónica para erradicar HCV-RNA detectável envolvendo uma terapia de combinação usando uma quantidade terapeuticamente eficaz de derivado de ribavirin da fórmula (I) e uma quantidade terapeuticamente eficaz de interferon alfa por um período de tempo de a partir de 20 até 80 semanas.
BR9915546-0A 1998-10-16 1999-10-14 Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica BR9915546A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PCT/US1999/021448 WO2000023454A1 (en) 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
BR9915546A true BR9915546A (pt) 2001-08-14

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915546-0A BR9915546A (pt) 1998-10-16 1999-10-14 Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica

Country Status (20)

Country Link
EP (1) EP1121369B1 (pt)
JP (1) JP2002527522A (pt)
CN (1) CN1330658A (pt)
AT (1) ATE284408T1 (pt)
AU (1) AU762395B2 (pt)
BR (1) BR9915546A (pt)
CA (1) CA2346447C (pt)
CZ (1) CZ20011130A3 (pt)
DE (1) DE69922529T2 (pt)
ES (1) ES2229820T3 (pt)
HU (1) HUP0200447A2 (pt)
ID (1) ID29187A (pt)
IL (1) IL142423A0 (pt)
NO (1) NO20011789L (pt)
NZ (1) NZ510811A (pt)
PL (1) PL347268A1 (pt)
RU (1) RU2001113268A (pt)
SK (1) SK4742001A3 (pt)
TR (1) TR200101085T2 (pt)
WO (1) WO2000023454A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
NZ545159A (en) * 2003-08-13 2009-03-31 Smith Howard J & Ass Pty Ltd Method of treating viral infections
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
EP2198870A4 (en) 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
PH12014500832A1 (en) 2011-10-21 2022-12-02 Abbvie Inc Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP5677646B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド Ｈｃｖの治療に使用するためのｄａａの（例えばａｂｔ−０７２もしくはａｂｔ−３３３との）併用治療
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
AU2017312116A1 (en) 2016-08-17 2019-03-07 Solstice Biologics, Ltd. Polynucleotide constructs
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
US20240325419A1 (en) 2022-05-05 2024-10-03 Abdula Kurkayev Pharmaceutical composition for restoring physiological processes and cells of organism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP0942916A2 (en) * 1996-11-12 1999-09-22 Medivir Aktiebolag Nucleosides

Also Published As

Publication number Publication date
ES2229820T3 (es) 2005-04-16
AU1197500A (en) 2000-05-08
DE69922529D1 (de) 2005-01-13
HUP0200447A2 (en) 2002-06-29
ATE284408T1 (de) 2004-12-15
CZ20011130A3 (cs) 2001-08-15
CN1330658A (zh) 2002-01-09
EP1121369B1 (en) 2004-12-08
EP1121369A1 (en) 2001-08-08
WO2000023454A1 (en) 2000-04-27
DE69922529T2 (de) 2005-12-15
PL347268A1 (en) 2002-03-25
NO20011789D0 (no) 2001-04-09
AU762395B2 (en) 2003-06-26
ID29187A (id) 2001-08-09
SK4742001A3 (en) 2001-11-06
JP2002527522A (ja) 2002-08-27
TR200101085T2 (tr) 2001-08-21
CA2346447C (en) 2006-01-31
IL142423A0 (en) 2002-03-10
NZ510811A (en) 2003-06-30
NO20011789L (no) 2001-06-11
CA2346447A1 (en) 2000-04-27
RU2001113268A (ru) 2003-09-27

Similar Documents

Publication Publication Date Title
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
BR0113115A (pt) Tratamento de hepatite c com timosina, interferon e ribavirina
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
MX9708885A (es) Uso de ribavirin e interferon alfa para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.